Sign in →

Test Code BCL2IGH Gene BCL2-IGH Gene Rearrangement

Performing Laboratory

LabCorp

Methodology

Polymerase chain reaction (PCR); gel electrophoresis

Reference Values

See Report

 

Includes:  Major breakpoint region (MBR) and minor cluster region (mcr)

Test Classification and CPT Coding

81402

 

LOINC:  21095-5

Physician Office Specimen Requirements

Container/Tube: Lavender-top (EDTA) tube, yellow-top (ACD-A) tube, or tissue in lymph node transport bottle

Specimen: Whole blood, bone marrow, fresh or frozen tissue, fixed-cell pellet 7 mL whole blood, 2 mL bone marrow,or 0.5 g tissue ( 3 mL whole blood min)

Transport Temperature: Room Temperature

 

Collection: Specimens should arrive in the laboratory within 24 hours of collection

 

Used For

The majority of follicular lymphomas are characterized by t(14;18) (q32;q21). This translocation joins the BCL2 gene on chromosome 14, resulting in the overproduction of the BCL2 protein, a potent apoptosis inhibitor. There are two common breakpoint regions involving BCL2 with approximately 65% of the breakpoints occurring at the major breakpoint region (MBR) and approximately 10% occurring at the minor cluster region (mcr). The BCL2-IGH translocation is also observed in 20% to 30% of diffuse large B-cell lymphomas. The ability to detect the t(14;18) translocation by means of polymerase chain reaction (PCR) allows for rapid assessment of the presence of this translocation. This is of significant clinical utility for defining the cause of the lymphoma and for monitoring minimal residual disease.

Limitations

The absence of a detectable fusion product does not exclude the presence of a rearrangement outside of the two breakpoint regions evaluated, or the presence of a B-cell lymphoma without an underlying BCL2-IGH translocation. In addition, it is important to note that the BCL2-IGH gene rearrangement has also been detected at low levels in some apparently benign hyperplastic lymphoid tissues.

 

Computer Interface Code

PDM #  1859733